Maryam Fouladi, MD, MSc

Dr. Fouladi is Professor and Medical Director of the Brain Tumor Center and the Marjorie Johnson Chair of Translational Brain Tumor Research. She served as Chair of the Pediatric Brain Tumor Consortium (PBTC) and currently chairs the Children’s Oncology Group (COG) Central Nervous System Committee. Dr. Fouladi has extensive experience with the development and conducting of phase I/II trials and preclinical development and pharmacology of new drugs in children with brain tumors. She also serves on the US Food and Drug Administration’s (FDA) Best Pharmaceuticals for Children (BPCA) Advisory Board.

Darren Hargrave, MB, ChB (Hons), MD

Dr. Hargrave is an associate professor and consultant pediatric neuro-oncologist at the Great Ormond Street Hospital for Children and University College London. Dr. Hargrave’s research focuses on developing ‘better and kinder’ therapies for children with central nervous system tumors. He is one of the most active clinical trial researchers in Europe in the field of pediatric neuro-oncology, and he chairs the UK New agents Group for Childhood Cancer and is a member of the clinical trial committees of both the Innovative therapies for Children with Cancer (ITCC) and the European Society for Pediatric Oncology (SIOPE) Brain groups.

Peter de Blank, MD, MSCE

Dr. de Blank is associate professor of Pediatrics in the division of oncology at Cincinnati Children’s Hospital Medical Center where he leads efforts in cancer imaging. He serves as the chair of the diffusion tensor imaging ancillary study in the international NF1 optic pathway glioma natural history study. He has experience in clinical trial design, biomarker validation and imaging endpoints.

Renee Doughman, PhD, CCRP
Operations Director

Dr. Doughman completed her undergraduate degree in biochemistry and completed a PhD in pharmacology from the University of Wisconsin. She has served as the regulatory liaison for the Cancer and Blood Diseases institute at Cincinnati Children’s Hospital Medical Center, the Pediatric Brain Tumor Consortium (PBTC) and the International Diffuse Intrinsic Pontine Gioma Registry. Dr. Doughman has over 10 years of extensive regulatory experience including conduct of FDA-regulated clinical trials, protocol development and clinical trial management experience overseeing oncology clinical trials.

Michelle Deutsch, MS, CSSBB
Project Manager

Michelle brings the CONNECT team over 20 years of industry experience in project management and process improvement. She has a MS in Organizational Leadership and has been involved with the American Society for Quality (ASQ) in their Human Development and Leadership Division and was honored with their Gryna Award in 2012. She became a Certified Six Sigma Black Belt through ASQ in 2017. Michelle will use her experience to build and support a solid infrastructure for CONNECT to continue to develop and grow.

Michael Price, MPA
Protocol Coordinator

Mr. Price is responsible for LOI and protocol development including protocol amendments, regulatory oversight, and data monitoring and site management. He works closely with the Operations Director to provide project support during study start-up, and works with sites to ensure that all protocol-specific operations are in place in order for site activation. He has over 4 years of experience working in clinical research field.

Keith Desserich
Patient Advocate

Mr. Desserich is a father of a child diagnosed with diffuse intrinsic pontine glioma. After his daughter’s passing in 2007, he co-founded The Cure Starts Now Foundation, which today has over 30 locations worldwide and has funded over $10 million in cancer research. He is the President of the Pediatric Brain Tumor Consortium Foundation, a member of the PBTC Steering Council and founder of the DIPG Collaborative. He is also an entrepreneur with professional experience in business development for over 20 years.